$NOVO B (+1,67 %) had been on my watch list for some time.
After the setback of the last few weeks, I have now added a first position to my portfolio.
Even if the hype surrounding the well-known weight loss injections could slowly level off or lose momentum, I am of the opinion that Novo Nordisk is a good choice in the health sector.
The predominantly unhealthy Western diet boosts the business model and allows Novo Nordisk to swim in money through the sale of its insulin preparations alone.
If the share price falls further, I will definitely buy more here.
